Clinical Trials Logo

Advanced Solid Tumor clinical trials

View clinical trials related to Advanced Solid Tumor.

Filter by:

NCT ID: NCT05120596 Recruiting - Clinical trials for Advanced Solid Tumor

First in Human Study of T3P-Y058-739 (T3P)

Start date: April 26, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a first in human, phase I/II open-label, dose-finding, safety, and proof-of-concept clinical trial of T3P-Y058-739, a genetically-modified, live attenuated strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumors.

NCT ID: NCT05119933 Recruiting - Clinical trials for Advanced Solid Tumor

A Phase 1/2, Study of YL-15293 in Subjects With Advanced Solid Tumors With a KRAS G12C Mutation

Start date: November 9, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a Phase 1/2, open-label, multicenter study designed to evaluate the maximum tolerated, safety, tolerability and PK of oral YY-15293 in patients with advanced solid tumors with a KRAS G12C mutation, to confirm the recommended phase 2 dose of YY-15293, and to obtain preliminary efficacy information in patients with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation.

NCT ID: NCT05118841 Recruiting - Clinical trials for Advanced Solid Tumor

Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors

Start date: January 3, 2022
Phase: Phase 1
Study type: Interventional

A Phase 1, first-in-human, open-label, multicenter, dose escalation and dose expansion study to investigate the safety, tolerability, PK, pharmacodynamics, and preliminary antitumor activity of ZX-4081 administered orally (PO) twice daily (BID) in 28-day cycles in patients with Advanced Solid Tumors.

NCT ID: NCT05117476 Recruiting - Clinical trials for Advanced Solid Tumor

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Start date: October 29, 2021
Phase: Phase 1
Study type: Interventional

CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.

NCT ID: NCT05109442 Recruiting - Clinical trials for Advanced Solid Tumor

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

Start date: November 19, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.

NCT ID: NCT05107011 Recruiting - Clinical trials for Advanced Solid Tumor

Phase I/II Clinical Trial of LBL-015 for Injection

Start date: November 5, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

A phase I/II clinical study evaluating LBL-015 in the treatment of subjects with advanced solid tumors

NCT ID: NCT05103683 Recruiting - Ovarian Cancer Clinical Trials

First in Human Study of TORL-1-23 in Participants With Advanced Cancer

TRIO049
Start date: November 17, 2021
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-1-23 in patients with advanced cancer

NCT ID: NCT05103358 Active, not recruiting - Cancer Clinical Trials

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Start date: February 15, 2022
Phase: Phase 2
Study type: Interventional

A Phase 2 multi-center open-label basket trial of nab-sirolimus for adult and adolescent patients with malignant solid tumors harboring pathogenic inactivating alterations in TSC1 or TSC2 genes

NCT ID: NCT05103345 Recruiting - Clinical trials for Advanced Solid Tumor

Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor

Start date: April 19, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

Objectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes at OBD doses. Study Rationale: The mechanism of action for SGN1 is based on the fact that most tumors are methionine dependent. SGN1 is designed to be used as a tumor therapeutic bacterium that can preferentially replicate and accumulate in tumors and starve them of essential amino acids by delivering the oncolytic enzyme L-Methioninase. Patient Population: Patients presenting with histologically confirmed advanced and/or metastatic solid tumors that are refractory to standard therapy and for which no other conventional therapy exists.

NCT ID: NCT05103046 Recruiting - Clinical trials for Advanced Solid Tumor

First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors

Start date: December 23, 2021
Phase: Phase 1
Study type: Interventional

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of UCT-03-008 in patients with advanced solid tumors.